ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)
$4.65 -0.18 (-3.7267%)
Analysed ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) News Sources
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
03-04-2026
yahoo.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
01-04-2026
yahoo.com
Atara Biotherapeutics: Q4 Earnings Snapshot
16-03-2026
yahoo.com
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
16-03-2026
yahoo.com
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
12-03-2026
yahoo.com
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
03-03-2026
biopharmadive.com
Atara Biotherapeutics Provides a Business Update
23-02-2026
yahoo.com
Top Midday Decliners
13-01-2026
yahoo.com
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
12-01-2026
yahoo.com
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
12-01-2026
biopharmadive.com
What is the current price of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The current price of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is $4.65.
ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) since the previous trading day is $-0.18.
ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) since the previous trading day is -3.7267%.
What is the most recent average sentiment score for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The most recent average sentiment score for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The most recent sentiment for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is .
SEC-8K** Filing Available For ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.